Balinatunfib is being developed as a potential new treatment for patients with psoriasis that selectively inhibits TNFR1 signalling to potentially stop or slow the disease-causing processes, while preserving signals initiated through TNFR2.

#Psoriasis

psoriasisclub.org/thread-8424....

Balinatunfib is an oral small molecule that inhibits TNFα by stabilizing a non-functional trimer, blocking receptor binding. It shows antinflammatory efficacy like biologics but avoids their drawbacks, offering better compliance and CNS access for TNFα-mediated disease treatment.
[Credit: A.Dömling]

An Highlight article just accepted in #ChemMedChem (@chemistryeurope.bsky.social) spotlights #balinatunfib, an orally available small molecule jointly developed by Sanofi and UCB preventing TNFα from effectively binding to its receptors.

chemistry-europe.onlinelibrary.wiley.com/doi/10.1002/...

Global Project Head - Immunology and Inflammation - Balinatunfib - Cambridge Job educativ.net/jobs/job/35859...

Global Project Head - Immunology and Inflammation - Balinatunfib - Cambridge Job educativ.net/jobs/job/35859...

Global Project Head - Immunology and Inflammation - Balinatunfib - Cambridge Job educativ.net/jobs/job/35859...

Global Project Head - Immunology and Inflammation - Balinatunfib - Cambridge Job educativ.net/jobs/job/35859...

Global Project Head - Immunology and Inflammation - Balinatunfib - Cambridge Job educativ.net/jobs/job/35859...

Global Project Head - Immunology and Inflammation - Balinatunfib - Cambridge Job educativ.net/jobs/job/35859...

Global Project Head - Immunology and Inflammation - Balinatunfib - Cambridge Job educativ.net/jobs/job/35859...